Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients with High-Risk MDS and AML

Principal Investigator:

Guillermo Garcia-Manero

Treatment Agent:

Cytarabine; Idarubicin; Vorinostat

Study Status:

Terminated

Study Description:

The goal of this clinical research study is to find the highest safe dose of
vorinostat that can be given in combination with idarubicin and ara-C for the
treatment of AML and high-risk MDS.

Once the highest safe dose is found, researchers will then try to learn if this
combination treatment can help to control AML and high-risk MDS in newly
diagnosed patients. The safety of this treatment combination will also be
studied.